Safety and immunogenicity of Ad26.COV2.S in adolescents: Phase 2 randomized clinical trial

Safety and immunogenicity of Ad26.COV2.S in adolescents: Phase 2 randomized clinical trial

We conducted a randomized, Phase 2 trial to assess the safety and humoral immunogenicity of reduced doses/dose volume of the standard dose of Ad26.COV2.S COVID-19 vaccine (5 × 1010 viral particles [vp]) in healthy adolescents aged 12–17 years. Participants were randomly assigned to receive Ad26.COV2...

Full description

Saved in:

Bibliographic Details
Main Authors:	Jelena Tica, Veronica V. Rezelj, Benoit Baron, Vitalija van Paassen, Javier Zaidman, Lee Fairlie, Gert Scheper, Mathieu Le Gars, Frank Struyf, Macaya Douoguih, Javier Ruiz-Guiñazú
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2025-12-01
Series:	Human Vaccines & Immunotherapeutics
Subjects:	Ad26.COV2.S COVID-19 vaccine adolescent immunogenicity safety virus vector vaccine
Online Access:	https://www.tandfonline.com/doi/10.1080/21645515.2025.2450120
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Safety, reactogenicity, and immunogenicity of Ad26.COV2.S co-administered with a quadrivalent standard-dose or high-dose seasonal influenza vaccine: a non-inferiority randomised controlled trialResearch in context
by: Gabriela Tapia-Calle, et al.
Published: (2025-01-01)

Safety and immunogenicity of an mRNA-1273 vaccine booster in adolescents
by: Amparo L. Figueroa, et al.
Published: (2025-12-01)

SHASI-ML: a machine learning-based approach for immunogenicity prediction in Salmonella vaccine development
by: Ottavia Spiga, et al.
Published: (2025-02-01)

Immunogenicity and safety of a COVID-19 DNA vaccine in healthy adults and elderly: A randomized, observer-blind, placebo-controlled phase 2 trial
by: Siyue Jia, et al.
Published: (2025-12-01)

Comprehensive review of preclinical evaluation strategies for COVID-19 vaccine candidates: assessing immunogenicity, toxicology, and safety profiles
by: Delaram Doroud, et al.
Published: (2025-02-01)

Reactogenicity and Immunogenicity Against MPXV of the Intradermal Administration of Modified Vaccinia Ankara Compared to the Standard Subcutaneous Route
by: Valentina Mazzotta, et al.
Published: (2024-12-01)

Immunogenicity of the 9-valent human papillomavirus vaccine: Post hoc analysis from five phase 3 studies
by: Anna R. Giuliano, et al.
Published: (2025-12-01)

Longitudinal immunogenicity cohort study of SARS-CoV-2 mRNA vaccines across individuals with different immunocompromising conditions: heterogeneity in the immune response and crucial role of Omicron-adapted booster dosesResearch in context
by: Annalisa Ciabattini, et al.
Published: (2025-03-01)

Sustained immunogenicity of bivalent protein COVID-19 vaccine SCTV01C against antigen matched and mismatched variants
by: Guiqiang Wang, et al.
Published: (2025-12-01)

Immunogenicity and safety of a live attenuated varicella vaccine in children aged 1 to 12 years: A double-blind, randomized, parallel-controlled phase III clinical trial in China
by: Shiyuan Wang, et al.
Published: (2025-12-01)

Immunogenicity and safety of a live attenuated varicella vaccine in healthy subjects aged between 13 to 55 years: a double-blind, randomized, active-controlled phase iii clinical trial in China
by: Yang Zhang, et al.
Published: (2025-12-01)

Safety and Immunogenicity of the Tetravalent Recombinant COVID-19 Protein Vaccine SCTV01E in Children and Adolescents Aged 3 to 17 Years: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial
by: Fengcai Zhu, et al.
Published: (2025-01-01)

Development and Evaluation of the Immunogenic Potential of an Unmodified Nucleoside mRNA Vaccine for Herpes Zoster
by: Shun Zhang, et al.
Published: (2025-01-01)

Immunogenic dying cells elicit potent anti-tumor T cell immunity against lung metastasis and tumorigenesis
by: Min Hu, et al.
Published: (2025-01-01)

Beyond Needles: Immunomodulatory Hydrogel-Guided Vaccine Delivery Systems
by: Md Mohosin Rana, et al.
Published: (2024-12-01)

Immunogenicity of HIV-1 <i>Env</i> mRNA and <i>Env-Gag</i> VLP mRNA Vaccines in Mice
by: Qi Ma, et al.
Published: (2025-01-01)

Expert consensus and recommendations on the live attenuated hepatitis A vaccine and immunization practices in India
by: Nitin Shah, et al.
Published: (2025-12-01)

Computational design, expression, and characterization of a Plasmodium falciparum multi-epitope, multi-stage vaccine candidate (PfCTMAG)
by: Joan A. Chick, et al.
Published: (2025-01-01)

Candidate vaccine construction against tick-born encephalitis based on hybrid recombinant flagG-protE-protein
by: P. A. Belavin, et al.
Published: (2018-01-01)

CoviWall, a whole-virion-inactivated B.1.617.2 vaccine candidate, induces potent humoral and Th1 cell response in mice and protects against B.1.617.2 strain challenge in Syrian hamsters
by: Jyotsna Dandotiya, et al.
Published: (2025-01-01)

A clinical study of the immunogenicity and protective potency of a live recombinant GamLPV vaccine for intranasal use for the prevention of whooping cough in adult volunteers
by: Alevtina A. Lidzhieva, et al.
Published: (2024-12-01)

Immunogenicity and safety of a live-attenuated SARS-CoV-2 vaccine candidate based on multiple attenuation mechanisms
by: Mie Suzuki Okutani, et al.
Published: (2025-02-01)

Immunogenicity and vaccine efficacy of Actinobacillus pleuropneumoniae-derived extracellular vesicles as a novel vaccine candidate
by: Su Hyun Park, et al.
Published: (2025-12-01)

Persistence of the Immune Response to an Intramuscular Bivalent (GI.1/GII.4) Norovirus Vaccine in Adults
by: Geert Leroux-Roels, et al.
Published: (2025-01-01)

Inactivation of Zika Virus with Hydroxypropyl-Beta-Cyclodextrin
by: Cory R. Hewitt, et al.
Published: (2025-01-01)

COVID-19 Vaccine Booster Dose Fails to Enhance Antibody Response to Omicron Variant in Reinfected Healthcare Workers
by: Leire Fernández-Ciriza, et al.
Published: (2025-01-01)

A SARS‐CoV‐2 EG.5 mRNA vaccine induces a broad‐spectrum immune response in mice
by: Hongyu Wang, et al.
Published: (2025-01-01)

The role of new hepatitis B vaccines in South Africa
by: G U van Zyl, et al.
Published: (2024-02-01)

Evaluating passive immunity in piglets from sows vaccinated with a PEDV S protein subunit vaccine
by: Jiajia Liu, et al.
Published: (2025-01-01)

The mRNA-1647 vaccine: A promising step toward the prevention of cytomegalovirus infection (CMV)
by: Adewunmi Akingbola, et al.
Published: (2025-12-01)

Proceedings of the 14th European immunogenicity platform open symposium on immunogenicity of biopharmaceuticals
by: Sophie Tourdot, et al.
Published: (2024-12-01)

Immunogenicity of Type IV Pilin Proteins from <i>Clostridium perfringens</i> in Chickens
by: Audrey Charlebois, et al.
Published: (2025-01-01)

Immunogenicity and protective efficacy of a multi-antigenic adenovirus-based vaccine candidate against Mycobacterium tuberculosis
by: Jin-Seung Yun, et al.
Published: (2025-01-01)

Adjuvanted subunit intranasal vaccine reduces SARS-CoV-2 onward transmission in hamsters
by: Yongjun Sui, et al.
Published: (2025-02-01)

Study of immunobiological properties of avian adenovirus serotype 2-based vaccine against adenovirus infection
by: A. A. Perepecha, et al.
Published: (2018-04-01)

Assessing the effect of beta-propiolactone inactivation on the antigenicity and immunogenicity of cluster 2.1 duck Tembusu virus
by: Kanana Rungprasert, et al.
Published: (2025-03-01)

The impact of vaccines and vaccinations: Challenges and opportunities for modelers
by: Roy Curtiss III
Published: (2010-12-01)

Parental Attitudes, Motivators and Barriers Toward Children’s Vaccination in Poland: A Scoping Review
by: Krystyna Szalast, et al.
Published: (2025-01-01)

Mutations in the <i>A34R</i> gene increase the immunogenicity of vaccinia virus
by: S. N. Shchelkunov, et al.
Published: (2021-04-01)

Modifying non-coding regions of linear DNA vaccines to explore the interplay of expression and inflammation in immunogenicity
by: David C. Stirling, et al.
Published: (2025-12-01)